Cargando…
Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Ar...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398743/ https://www.ncbi.nlm.nih.gov/pubmed/28539802 http://dx.doi.org/10.2147/EB.S94443 |
_version_ | 1783230521407438848 |
---|---|
author | McLeod, D Scott Lutty, Gerard A |
author_facet | McLeod, D Scott Lutty, Gerard A |
author_sort | McLeod, D Scott |
collection | PubMed |
description | Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Arnall Patz in an effort to experimentally determine the effects of hyperoxia on the development of the retinal vasculature. The canine OIR model has many characteristics in common with human retinopathy of prematurity. Exposure of 1-day-old dogs to hyperoxia for 4 days causes a vaso-obliteration throughout the retina. Vasoproliferation, after the animals have returned to room air, is robust. The initial small preretinal neovascular formations anastomose to form large preretinal membranes that eventually cause tractional retinal folds. The end-stage pathology of the canine model is similar to stage IV human retinopathy of prematurity. Therefore, canine OIR is an excellent forum to evaluate the response to drugs targeting VEGF and its receptors. Evaluation of an antibody to VEGF-R2 and the VEGF-Trap demonstrated that doses should be titered down so that preretinal neovascularization is inhibited but retinal revascularization is able to proceed, vascularizing peripheral retina and preventing it from being a source of VEGF. |
format | Online Article Text |
id | pubmed-5398743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53987432017-05-24 Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity McLeod, D Scott Lutty, Gerard A Eye Brain Original Research Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Arnall Patz in an effort to experimentally determine the effects of hyperoxia on the development of the retinal vasculature. The canine OIR model has many characteristics in common with human retinopathy of prematurity. Exposure of 1-day-old dogs to hyperoxia for 4 days causes a vaso-obliteration throughout the retina. Vasoproliferation, after the animals have returned to room air, is robust. The initial small preretinal neovascular formations anastomose to form large preretinal membranes that eventually cause tractional retinal folds. The end-stage pathology of the canine model is similar to stage IV human retinopathy of prematurity. Therefore, canine OIR is an excellent forum to evaluate the response to drugs targeting VEGF and its receptors. Evaluation of an antibody to VEGF-R2 and the VEGF-Trap demonstrated that doses should be titered down so that preretinal neovascularization is inhibited but retinal revascularization is able to proceed, vascularizing peripheral retina and preventing it from being a source of VEGF. Dove Medical Press 2016-05-20 /pmc/articles/PMC5398743/ /pubmed/28539802 http://dx.doi.org/10.2147/EB.S94443 Text en © 2016 McLeod and Lutty. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research McLeod, D Scott Lutty, Gerard A Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
title | Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
title_full | Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
title_fullStr | Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
title_full_unstemmed | Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
title_short | Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
title_sort | targeting vegf in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398743/ https://www.ncbi.nlm.nih.gov/pubmed/28539802 http://dx.doi.org/10.2147/EB.S94443 |
work_keys_str_mv | AT mcleoddscott targetingvegfincanineoxygeninducedretinopathyamodelforhumanretinopathyofprematurity AT luttygerarda targetingvegfincanineoxygeninducedretinopathyamodelforhumanretinopathyofprematurity |